NCEL (NewcelX) Beta: 2.7992 (As of Jul. 06, 2026)


NCEL NewcelX Ltd NCEL
33 GF Score
Price $3.83
! 4 Warning Signs
View Full Analysis

What is NewcelX Beta?

NewcelX NCEL -0.52% 33 Beta is 2.7992 as of Jul. 06, 2026. GuruFocus rates NCEL with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-06), NewcelX's Beta is 2.7992.


NewcelX  (NAS:NCEL) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


NewcelX Beta Related Terms


NewcelX Beta Historical Data

* Premium members only.

The historical data trend for NewcelX's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewcelX Beta Chart

NewcelX Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.22 0.68

NewcelX Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.06 -0.22 0.21 0.68

NCEL vs LPCN, PTN, ALLR: Beta Comparison

For the Biotechnology subindustry, NewcelX's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NewcelX Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewcelX's Beta distribution charts can be found below:

* The bar in red indicates where NewcelX's Beta falls into.


NCEL
33GF Score
NewcelX Ltd NCEL
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewcelX Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.7992 mean?
NewcelX (NCEL) has a Beta of 2.7992 as of Jul. 06, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for NewcelX and its competitors.
Is NewcelX's Beta too high?
NewcelX's current Beta is 2.7992. Overall, NewcelX has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does NewcelX's Beta compare to LPCN and PTN?
NewcelX's Beta of 2.7992 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for NewcelX and its competitors. NewcelX's current Beta is 2.7992. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewcelX stock overvalued right now?
NewcelX (NCEL) has a current Beta of 2.7992. The current Beta is 2.7992. NewcelX's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For NewcelX (NCEL), the current Beta is 2.7992 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NewcelX Business Description

Address Hohstrasse 1, Kloten, CHE, 8302
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
33GF Score

Get the complete analysis for NCEL

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.83
Price